HOOK - Hookipa Pharma Inc Stock Price, Fair Value and News

0.89USD+0.08 (+9.88%)Market Closed

Market Summary

USD0.89+0.08

Market Closed

9.88%

HOOK Stock Price

View Fullscreen

HOOK RSI Chart

HOOK Valuation

Market Cap

18.2M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

0.9

EV/EBITDA

1.28

Price/Free Cashflow

-0.3

HOOK Price/Sales (Trailing)

HOOK Profitability

EBT Margin

-403.46%

Return on Equity

-90.79%

Return on Assets

-50.56%

Free Cashflow Yield

-338.76%

HOOK Fundamentals

HOOK Revenue

Revenue (TTM)

20.1M

Rev. Growth (Yr)

-5.38%

Rev. Growth (Qtr)

7.86%

HOOK Earnings

Earnings (TTM)

-81.6M

Earnings Growth (Yr)

-101.59%

Earnings Growth (Qtr)

-30.17%

Breaking Down HOOK Revenue

Last 7 days

21.9%

Last 30 days

23.6%

Last 90 days

27.1%

Trailing 12 Months

-11.9%

How does HOOK drawdown profile look like?

HOOK Financial Health

Current Ratio

3.5

HOOK Investor Care

Diluted EPS (TTM)

-0.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	16.0M	15.9M	20.6M	20.1M
2022	14.6M	12.0M	10.3M	14.2M
2021	21.2M	19.9M	19.7M	18.4M
2020	13.4M	16.0M	18.0M	19.6M
2019	9.9M	13.3M	13.4M	11.9M
2018	0	0	0	7.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Hookipa Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 21, 2023	kandera reinhard	bought	5,075	0.725	7,000	chief financial officer
Aug 16, 2023	kandera reinhard	bought	5,712	0.714	8,000	chief financial officer
Jul 11, 2023	aldag jorn	bought	4,142	0.8284	5,000	chief executive officer
Jul 07, 2023	aldag jorn	bought	4,050	0.81	5,000	chief executive officer
Jul 05, 2023	aldag jorn	bought	4,450	0.89	5,000	chief executive officer
Jul 03, 2023	aldag jorn	bought	4,455	0.8911	5,000	chief executive officer
Jun 30, 2023	kandera reinhard	bought	10,560	0.88	12,000	chief financial officer
Feb 01, 2022	necina roman	acquired	38,676	3.00	12,892	chief technology officer
Feb 01, 2022	baker christine d.	acquired	40,974	3.00	13,658	chief business officer
Feb 01, 2022	kandera reinhard	acquired	42,168	3.00	14,056	chief financial officer

Which funds bought or sold HOOK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	DLK Investment Management, LLC	unchanged	-	-3,136	22,784	0.01%
Apr 11, 2024	INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC	unchanged	-	-1,211	10,129	-%
Apr 10, 2024	Apella Capital, LLC	unchanged	-	1,778	16,645	-%
Apr 05, 2024	NBC SECURITIES, INC.	reduced	-36.84	-3,000	4,000	-%
Mar 11, 2024	VANGUARD GROUP INC	added	16.36	593,414	1,712,990	-%
Feb 27, 2024	Beaird Harris Wealth Management, LLC	sold off	-100	-57.00	-	-%
Feb 14, 2024	Knoll Capital Management, LLC	unchanged	-	1,070,370	4,469,080	3.70%
Feb 14, 2024	EcoR1 Capital, LLC	unchanged	-	891,434	3,721,970	0.10%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-48.45	-22,183	46,684	-%
Feb 14, 2024	BAKER BROS. ADVISORS LP	added	0.78	1,615,520	6,583,800	0.07%

Are Funds Buying or Selling HOOK?

Are funds buying HOOK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HOOK

No. of Funds

Unveiling Hookipa Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	4.8%	4,595,024	SC 13G/A
Feb 14, 2024	redmile group, llc	1.1%	1,063,769	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	9.99%	8,148,985	SC 13G/A
Dec 22, 2023	gilead sciences, inc.	19.4%	18,759,465	SC 13G/A
Sep 11, 2023	fmr llc	-	0	SC 13G/A
Jun 20, 2023	knoll capital management, llc	6.8%	5,517,385	SC 13G
Feb 14, 2023	deep track capital, lp	2.37%	1,240,369	SC 13G/A
Feb 14, 2023	gilead sciences, inc.	7.2%	3,759,465	SC 13G/A
Feb 14, 2023	ecor1 capital, llc	9.1%	4,973,489	SC 13G/A
Feb 14, 2023	redmile group, llc	9.9%	5,460,768	SC 13G/A

Recent SEC filings of Hookipa Pharma Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	8-K	Current Report
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	PRE 14A	PRE 14A

Hookipa Pharma Inc News

Latest updates

Hookipa Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	7.9%	7,407,000	6,867,000	2,679,000	3,176,000	7,828,000	2,230,000	2,746,000	1,445,000	3,895,000	3,874,000	5,378,000	5,301,000	5,163,000	4,040,000	6,685,000	3,696,000	3,618,000	2,038,000	4,051,000	2,235,000	5,080,000
Costs and Expenses	29.7%	38,302,000	29,537,000	24,151,000	25,833,000	21,416,000	23,223,000	21,173,000	21,592,000	25,942,000	25,040,000	24,667,000	24,473,000	20,357,000	20,446,000	15,911,000	16,155,000	16,843,000	15,614,000	17,680,000	12,890,000	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,680,000	12,890,000	-
S&GA Expenses	-11.0%	4,374,000	4,912,000	4,445,000	4,902,000	3,824,000	4,937,000	5,026,000	4,972,000	3,523,000	4,342,000	5,095,000	4,309,000	4,669,000	4,437,000	4,347,000	4,629,000	5,664,000	4,589,000	3,751,000	2,711,000	2,669,000
R&D Expenses	-14.1%	21,162,000	24,625,000	19,706,000	20,931,000	17,592,000	18,286,000	16,147,000	16,620,000	22,419,000	20,698,000	19,572,000	20,164,000	15,688,000	16,009,000	11,564,000	11,526,000	11,179,000	11,025,000	13,929,000	10,179,000	4,615,000
EBITDA Margin	-21.3%	-3.84	-3.17	-4.02	-3.89	-4.24	-6.70	-5.89	-4.86	-3.80	-3.12	-2.77	-2.14	-2.00	-2.00	-2.16	-2.99	-3.27	-2.43	-1.91	-1.97	-1.94
Interest Expenses	0%	49,000	49,000	97,000	122,000	108,000	105,000	231,000	243,000	227,000	234,000	218,000	219,000	199,000	194,000	166,000	227,000	227,000	227,000	210,000	213,000	200,000
Income Taxes	-	163,500	-	-	205,000	229,000	-	1,000	-	-	1,000	-	-	-	-	-	-	-109,000	9,000	100,000	-	21,000
Earnings Before Taxes	-29.3%	-24,654,500	-19,066,000	-18,016,000	-19,475,000	-12,082,000	-18,280,000	-16,355,000	-17,968,000	-21,234,500	-20,039,000	-17,153,000	-17,238,000	-12,474,500	-13,589,000	-7,092,000	-10,926,000	-10,353,000	-11,376,000	-11,979,000	-9,329,000	-1,895,000
EBT Margin	-20.8%	-4.03	-3.34	-4.26	-4.14	-4.54	-7.16	-6.32	-5.24	-4.10	-3.39	-3.04	-2.38	-2.25	-2.33	-2.48	-3.33	-3.60	-2.58	-2.05	-2.13	-2.13
Net Income	-30.2%	-24,818,000	-19,066,000	-18,016,000	-19,680,000	-12,311,000	-18,280,000	-16,356,000	-17,968,000	-21,234,500	-20,040,000	-17,153,000	-17,238,000	-12,475,000	-13,589,000	-7,092,000	-10,926,000	-10,244,000	-11,385,000	-12,079,000	-9,329,000	-1,892,000
Net Income Margin	-20.6%	-4.05	-3.36	-4.29	-4.17	-4.55	-7.16	-6.32	-5.24	-4.10	-3.39	-3.04	-2.38	-2.25	-2.32	-2.47	-3.33	-3.60	-2.59	-2.05	-2.13	-2.13
Free Cashflow	57.1%	-11,646,000	-27,137,000	-19,778,000	-3,122,000	12,538,000	-17,466,000	-19,991,000	-95,000	-18,384,000	-20,130,000	-25,356,000	-14,727,000	-11,806,000	-10,990,000	-11,587,000	-7,327,000	-9,839,000	-9,847,000	-11,588,000	-12,456,000	-6,626,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.6%	161	164	191	163	170	152	172	196	126	142	166	170	188	121	133	136	144	152	168	102	68.00
Current Assets	5.5%	147	139	168	140	147	130	149	171	102	119	143	153	172	106	118	121	128	136	151	85.00	62.00
Cash Equivalents	8.7%	117	108	136	110	112	101	119	142	67.00	83.00	103	128	143	82.00	93.00	105	114	124	135	71.00	49.00
Net PPE	-61.6%	8.00	20.00	18.00	18.00	18.00	17.00	17.00	17.00	16.00	15.00	13.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00	4.00
Liabilities	3.7%	71.00	69.00	79.00	80.00	68.00	38.00	40.00	48.00	36.00	34.00	40.00	30.00	32.00	29.00	29.00	27.00	26.00	26.00	32.00	30.00	24.00
Current Liabilities	3.5%	42.00	41.00	46.00	44.00	36.00	26.00	27.00	31.00	28.00	27.00	34.00	20.00	21.00	19.00	19.00	15.00	15.00	13.00	17.00	15.00	15.00
Shareholder's Equity	-5.5%	90.00	95.00	112	83.00	103	113	132	148	90.00	108	126	140	156	92.00	104	109	118	126	136	-	-
Retained Earnings	-7.2%	-369	-344	-325	-307	-287	-275	-257	-240	-222	-201	-181	-164	-147	-134	-121	-113	-103	-92.80	-81.39	-69.31	-59.98
Additional Paid-In Capital	4.8%	467	446	445	398	397	396	395	394	317	315	314	311	309	232	230	228	226	223	222	4.00	3.00
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26.00	26.00	26.00	18.00	15.00	10.00	1.00	1.00
Float	-	-	-	72.00	-	-	-	83.00	-	-	-	238	-	-	-	207	-	-	-	101	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	53.5%	-11,224	-24,119	-19,333	-2,848	13,137	-16,508	-18,359	1,733	-13,243	-17,644	-20,732	-14,397	-11,301	-10,365	-10,545	-7,128	-8,793	-9,485	-11,397	-12,056	-6,376
Share Based Compensation	-27.4%	417	574	696	658	1,001	1,040	1,381	1,621	1,777	1,719	2,627	1,521	2,265	2,147	2,151	2,094	2,104	1,872	1,206	383	250
Cashflow From Investing	86.0%	-422	-3,018	-445	-274	-599	-958	-1,632	-1,828	-5,141	-2,486	-4,624	-330	-505	-625	-1,042	-199	-1,046	-362	-191	-400	-250
Cashflow From Financing	3324.4%	21,249	-659	45,815	-735	-196	127	-2,953	75,293	-410	-11.00	85.00	101	75,076	-222	-150	-1,284	-883	-532	76,009	35,157	6.00

HOOK Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenue from collaboration and licensing	$ 20,129	$ 14,249	$ 18,448
Revenue from Contract with Customer, Product and Service [Extensible List]	hook:CollaborationAndLicensingMember	hook:CollaborationAndLicensingMember	hook:CollaborationAndLicensingMember
Operating expenses:
Research and development	$ (86,424)	$ (68,645)	$ (82,853)
General and administrative	(18,633)	(18,759)	(17,269)
Impairment expense	(12,766)	0	0
Total operating expenses	(117,823)	(87,404)	(100,122)
Loss from operations	(97,694)	(73,155)	(81,674)
Other income (expense):
Grant income	11,193	7,916	9,724
Interest income	5,293	1,633	27
Interest expense	(317)	(687)	(898)
Other income and (expenses), net	313	(392)	(2,843)
Total other income, net	16,482	8,470	6,010
Net loss before tax	(81,212)	(64,685)	(75,664)
Income tax expense	(368)	(230)	(1)
Net loss	(81,580)	(64,915)	(75,665)
Other comprehensive (loss) income:
Foreign currency translation (loss) gain, net of tax	(777)	(2,376)	1,287
Comprehensive loss	$ (82,357)	$ (67,291)	$ (74,378)
Net loss per share - basic	$ (0.86)	$ (0.99)	$ (2.30)
Net loss per share - diluted	$ (0.86)	$ (0.99)	$ (2.30)

HOOK Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 117,096	$ 112,488
Restricted cash		537
Accounts receivable	511	6,533
Receivable research incentives	18,760	15,479
Prepaid expenses and other current assets	10,749	12,159
Total current assets	147,116	147,196
Non-current assets:
Restricted cash	425	419
Property, plant and equipment, net	7,742	17,970
Operating lease right of use assets	5,473	4,006
Other non-current assets	581	863
Total non-current assets	14,221	23,258
Total assets	161,337	170,454
Current liabilities
Accounts payable	12,498	5,488
Deferred revenues	14,631	15,684
Operating lease liabilities, current	1,638	1,688
Accrued expenses and other current liabilities	12,101	11,178
Loans payable, current	1,120	1,594
Total current liabilities	41,988	35,632
Non-current liabilities
Loans payable, non-current		911
Operating lease liabilities, non-current	3,801	2,310
Deferred revenues, non-current	19,674	25,664
Other non-current liabilities	6,017	3,420
Total non-current liabilities	29,492	32,305
Total liabilities	71,480	67,937
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	467,041	397,349
Accumulated other comprehensive loss	(7,933)	(7,156)
Accumulated deficit	(369,261)	(287,681)
Total stockholders' equity	89,857	102,517
Total liabilities and stockholders' equity	161,337	170,454
Common stock
Stockholders' equity:
Common stock	10	5
Class A common stock
Stockholders' equity:
Common stock	$ 0	$ 0

About Hookipa Pharma Inc

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

CEO	Mr. Joern Aldag
WEBSITE	hookipapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	156

Hookipa Pharma Inc Frequently Asked Questions

What is the ticker symbol for Hookipa Pharma Inc? What does HOOK stand for in stocks?

HOOK is the stock ticker symbol of Hookipa Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hookipa Pharma Inc (HOOK)?

As of Fri Apr 26 2024, market cap of Hookipa Pharma Inc is 18.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOOK stock?

You can check HOOK's fair value in chart for subscribers.

What is the fair value of HOOK stock?

You can check HOOK's fair value in chart for subscribers. The fair value of Hookipa Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hookipa Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HOOK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hookipa Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether HOOK is over valued or under valued. Whether Hookipa Pharma Inc is cheap or expensive depends on the assumptions which impact Hookipa Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOOK.

What is Hookipa Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, HOOK's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 0.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOOK PE ratio will change depending on the future growth rate expectations of investors.